Revenue and Profit - Revenue for Q3 2023 was CNY 117,216,729.85, a decrease of 34.32% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 5,312,443.32, down 58.94% year-on-year[5] - The net profit excluding non-recurring gains and losses was CNY 3,281,402.64, a decline of 69.48% compared to the previous year[5] - Basic earnings per share for Q3 2023 was CNY 0.05, a decrease of 54.55% from the same period last year[6] - Net profit for Q3 2023 was CNY 21,376,634.95, a decline of 45.5% from CNY 39,380,724.76 in Q3 2022[22] - Basic earnings per share for Q3 2023 were CNY 0.20, down from CNY 0.35 in Q3 2022, representing a decrease of 42.9%[22] Assets and Liabilities - Total assets as of September 30, 2023, were CNY 2,215,428,582.95, an increase of 7.04% from the end of the previous year[6] - The company's total assets increased to CNY 2,215,428,582.95, compared to CNY 2,069,814,969.32 at the end of Q3 2022, reflecting a growth of 7.0%[19] - Total liabilities rose to CNY 1,210,352,681.70, up from CNY 1,088,654,608.48, marking an increase of 11.2% year-over-year[19] - The company's cash and cash equivalents decreased to CNY 850,417,020.84 from CNY 1,213,731,540.24, a decline of 30.0%[19] - Long-term investments slightly decreased to CNY 47,910,298.22 from CNY 48,080,730.74, a reduction of 0.35%[19] - The total equity attributable to shareholders increased to CNY 953,236,663.03 from CNY 928,089,864.99, reflecting a growth of 2.7% year-over-year[19] Cash Flow - Cash flow from operating activities showed a significant increase of 5,680.24% year-to-date, reaching CNY 9,403,225.49[5] - Net cash flow from operating activities increased significantly by 5,680.24% to ¥9,403,225.49 due to reduced cash outflows[13] - Total cash inflow from operating activities was ¥373,992,429.06, down from ¥430,847,358.70 year-over-year, representing a decrease of approximately 13.2%[24] - Cash outflow from operating activities was ¥364,589,203.57, slightly lower than ¥430,684,679.80 in the previous year, indicating a decrease of about 15.4%[24] - The net cash flow from investing activities was -¥310,421,621.20, an improvement from -¥363,861,510.23 in the same period last year[25] - Cash inflow from investing activities totaled ¥45,030,392.39, compared to ¥235,445.29 in the previous year, showing a substantial increase[25] - Cash outflow from investing activities was ¥355,452,013.59, down from ¥364,096,955.52 year-over-year, reflecting a decrease of approximately 2.0%[25] - The net cash flow from financing activities was -¥19,276,386.77, a significant decline from ¥392,968,457.22 in the previous year[25] - Total cash inflow from financing activities was ¥281,109,770.11, down from ¥588,484,292.91 year-over-year, indicating a decrease of about 52.3%[25] - The ending balance of cash and cash equivalents was ¥94,771,263.76, a decrease from ¥211,560,506.80 in the previous year, representing a decline of approximately 55.2%[25] Expenses and Other Financial Metrics - Total operating costs for Q3 2023 were CNY 372,954,404.95, down 8.3% from CNY 406,719,480.63 in Q3 2022[21] - The company reported a significant increase in research and development expenses to CNY 30,315,565.77, compared to CNY 29,530,625.12 in the previous year, indicating a focus on innovation[21] - Operating tax and additional fees increased by 60.27% to ¥767,812.69 due to new property-related taxes[11] - Sales expenses rose by 41.47% to ¥3,651,441.69 primarily from increased exhibition costs and sales channel expansion[11] - Financial expenses increased by 32.55% to ¥7,040,056.23 mainly due to higher interest costs and exchange rate fluctuations[11] - Other income surged by 153.47% to ¥4,102,504.02, attributed to increased government subsidies[11] - The company reported a significant reduction in credit impairment losses by 71.71% to -¥731,085.80 due to improved receivables recovery[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,287[15] - The largest shareholder, Zi Zuobin, holds 31.72% of shares, totaling 36,567,000 shares[15] Construction and Borrowings - The company reported a 113.58% increase in construction in progress, totaling CNY 879,911,849.83[10] - The company’s short-term borrowings decreased by 59.55% to CNY 130,086,333.33[10] - The company’s contract liabilities increased by 200.73% to CNY 1,672,684.81, indicating a rise in prepayments received[10] Audit Information - The company did not undergo an audit for the third quarter report[26]
共同药业(300966) - 2023 Q3 - 季度财报